01/31/23 7:30 AMNasdaq : SNOA partnershiplow floatSonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South KoreaSonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatology, eye, oral and nasalRHEA-AIvery positive
01/25/23 7:30 AMNasdaq : SNOA low floatSonoma Pharmaceuticals and EMC Pharma Announce Department of Defense DAPA Registration for Microcyn(R) Rx ProductsSonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatology, eye, oral and nasalRHEA-AIvery positive
01/04/23 7:30 AMNasdaq : SNOA low floatSonoma Pharmaceuticals Launches Two New Products Expanding Its Line of Office Dispense Products Exclusively for Dermatologists and Medical SpasSonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn ® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatology, eye, oral and nasalRHEA-AIpositive
11/14/22 4:15 PMNasdaq : SNOA earningslow floatSonoma Pharmaceuticals Reports Second Quarter 2023 Financial ResultsInternational sales increased by 18% in the six months ended September 30, 2022 compared to the same period prior year Gross profit percentage continues to trend upwards with the quarter ended September 30, 2022, coming in at 40% compared to 33% same period prior year Operating loss for the quarterRHEA-AIneutral
10/27/22 4:01 PMNasdaq : SNOA low floatSonoma Pharmaceuticals Launches Two New Dermatological Products for Over-The-Counter Use in the United StatesSonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal careRHEA-AIneutral
10/06/22 4:15 PMNasdaq : SNOA low floatSonoma Pharmaceuticals to Exhibit at Upcoming CPHI Conference in Frankfurt, GermanySonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, and dermatological conditions,RHEA-AIneutral
08/11/22 4:30 PMNasdaq : SNOA earningslow floatSonoma Pharmaceuticals Reports First Quarter 2023 Financial ResultsSonoma Pharmaceuticals, Inc.RHEA-AIneutral
08/02/22 4:30 PMNasdaq : SNOA partnershiplow floatSonoma Pharmaceuticals Launches MicrocynVS(R) Line of Products Exclusively for Veterinarian Use and Announces Partnership with DV Medical SupplySonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care,RHEA-AIvery positive
07/13/22 4:45 PMNasdaq : SNOA earningslow floatSonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2022 Financial ResultsSonoma Pharmaceuticals, Inc. (NASDAQ:SNOA),a global healthcare leader developing andRHEA-AIneutral
06/01/22 6:00 AMNasdaq : SNOA covid-19low floatSonoma Pharmaceuticals and MicroSafe Group DMCC Announce that U.S. EPA has Added Nanocyn® Hospital-Grade Disinfectant to List N for Use Against COVID-19Sonoma Pharmaceuticals, Inc., a global healthcare leader developing and producing patented Microcyn ® technology-based stabilized hypochlorous acid products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions and disinfectant use, and its partner, the MicroSafe Group DMCC, are pleased to announce that...RHEA-AIpositive